PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Clofarabine

Drugs in development · updated 30 October 2026

Clofarabine: clinical trials and development status

Other names and codes: Clolar, Evoltra, Ivozall

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 29 May 2006

As of 30 October 2026 Clofarabine is in 14 active clinical trials (recruiting or ongoing, phases I–III) for 22 diseases. The most advanced phase is III.

14Active trials
IIIMost advanced phase
22Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Clofarabine and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Acute myeloid leukemiaIII5NCT05477589
Precursor lymphoblastic lymphoma/leukemiaII–III4NCT03117751
LeukemiaIII3NCT05477589
LymphomaII–III2NCT03117751
NeoplasmIII1NCT05477589
Myelodysplastic SyndromesII3NCT01885689
Non-Hodgkin lymphomaII3NCT02727803
Chronic myelomonocytic leukemiaII2NCT01885689
Graft-versus-host diseaseII2NCT07566377
Hodgkin lymphomaII2NCT02727803
Langerhans-cell histiocytosisII2NCT02425904
Accelerated phase chronic myelogenous leukemiaII1NCT02727803
Acute biphenotypic leukaemiaII1NCT02727803
Bone marrow failureII1NCT04644016
Burkitt lymphomaII1NCT03136146
Chronic phase chronic myelogenous leukemiaII1NCT02727803
Crohn's diseaseI–II1NCT06986382
Hematologic neoplasmII1NCT06252870
HemoglobinopathiesII1NCT04644016
Myelodysplastic–myeloproliferative diseasesII1NCT02727803
Myeloproliferative disordersII1NCT04644016
Refractory anemia with excess of blastsII1NCT02727803

Everything on Clofarabine

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch